Molecular mechanisms underpinning sarcomas and implications for current and future therapy

  title={Molecular mechanisms underpinning sarcomas and implications for current and future therapy},
  author={Victoria Damerell and Michael Sean Pepper and Sharon Prince},
  journal={Signal Transduction and Targeted Therapy},
Sarcomas are complex mesenchymal neoplasms with a poor prognosis. Their clinical management is highly challenging due to their heterogeneity and insensitivity to current treatments. Although there have been advances in understanding specific genomic alterations and genetic mutations driving sarcomagenesis, the underlying molecular mechanisms, which are likely to be unique for each sarcoma subtype, are not fully understood. This is in part due to a lack of consensus on the cells of origin, but… 

Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness

An up-to-date overview of the different immunotherapy modalities as potential treatments for sarcoma is provided, to identify barriers posed by the Sarcoma microenvironment to immunotherapy, highlight their relevance for impeding effectiveness, and suggest mechanisms to overcome these barriers.

Complex Elucidation of Cells-of-Origin in Pediatric Soft Tissue Sarcoma: From Concepts to Real Life, Hide-and-Seek through Epigenetic and Transcriptional Reprogramming

How cellular reprogramming mediated by driver genes in STS can profoundly reshape the molecular and morphological features of a transformed cell and lead to erroneous interpretation of its cell-of-origin is discussed.

The c-Myc/TBX3 Axis Promotes Cellular Transformation of Sarcoma-Initiating Cells

The data described indicate that the c-Myc/TBX3 oncogenic molecular pathway may be a key mechanism that transforms hMSCs into sarcomas.

Targeting the oncogenic TBX3:nucleolin complex to treat multiple sarcoma subtypes.

These findings provide the first evidence thatTBX3 requires nucleolin to promote features of sarcomagenesis and that disruption of the oncogenic TBX3-nucleolin interaction by AS1411 may be a novel approach for treating sarcomas.

Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives

An overview of current diagnostic pitfalls and clinical management of MFS is provided and a look at future directions will be discussed.

Pan-sarcoma characterization of lncRNAs in the crosstalk of EMT and tumour immunity identifies distinct clinical outcomes and potential implications for immunotherapy

By integrative analysis on multi-omics profiling, the findings provide a comprehensive resource for understanding the functional role of lncRNA-mediated immune regulation in sarcomas, which may advance the understanding of tumour immune response and the development of lNCRNA-based immunotherapeutic strategies for sarcoma.

Established and Experimental Systemic Treatment Options for Advanced Liposarcoma

Surgical resection is the mainstay of treatment for patients with localized liposarcoma, and results from trials exploring experimental therapeutic options will further define the role that these new treatments will play in the management of the different subtypes of liposARcoma.

Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma

This study provides a preclinical rationale for the evaluation of AXL-targeting ADCs in the treatment of A XL-expressing sarcomas and demonstrated significant tumor growth delay, regression, and/or prolonged survival compared to isotype control ADC in 5/8 STS PDX models investigated.

Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives

The invention of genomically tailored treatment has resulted in a spectacular improvement in disease outcomes for a significant portion of cancer patients, and there is an increasing utilization of agnostic testing which involves the analysis of all potentially actionable genes across all tumor types.



CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets

Assessment of the prevalence and importance of CDK pathway alterations in sarcomas, highlighting the gap in knowledge for certain CDKs in these tumors, and insight into studies focused on CDK inhibition for sarcoma treatment are provided.

Modeling sarcomagenesis using multipotent mesenchymal stem cells

The existing MSC-based models of sarcoma are reviewed and the most common mechanisms leading to tumoral transformation of MSCs and sarcomagenesis are discussed, which will be undoubtedly valuable in providing a better understanding about the etiology and pathogenesis of mesenchymal cancer.

Mechanisms of sarcomagenesis.

Sarcoma Spheroids and Organoids—Promising Tools in the Era of Personalized Medicine

Recent advances and future perspectives of spheroid and organoid in vitro models of rare sarcomas that can be used to investigate individual molecular biology and predict clinical responses are summarized.

Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies

A broad overview of the current literature on targeting neomorphic features of fusion oncogenes found in Ewing sarcoma, alveolar rhabdomyosarcomas, and synovial sarcomas is provided, and a perspective for future developments is given.

Preclinical In Vivo Modeling of Pediatric Sarcoma—Promises and Limitations

This review of available approaches to model sarcoma in vivo focused on genetically engineered and patient-derived mouse models, compared strengths and weaknesses, and finally explored possibilities and limitations to utilize these models to advance both biological understanding as well as clinical diagnosis and therapy.

Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.

Notch signaling in pediatric soft tissue sarcomas

An outline of recently gathered evidence on the role of Notch signaling in soft tissue sarcomas is presented, highlighting its importance in tumor cell biology.

Molecular pathology of sarcomas.

This review points out the clinical projection of sarcomagenesis elucidation and knowledge of diverse types of molecular alterations in sarcomas, as well as the identification of reliable molecular markers and possible therapeutic targets.